Toll Free: 1-888-928-9744

Contact Lenses - Medical Devices Pipeline Assessment, 2016

Published: Apr 1, 2016 | Pages: 172 | Publisher: GlobalData | Industry: Medical Devices | Report Format: Electronic (PDF)

Contact Lenses - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, "Contact Lenses - Medical Devices Pipeline Assessment, 2016" provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Contact Lenses under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons To Buy

The report enables you to - 
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Contact Lenses under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 10 2 Introduction 11 2.1 Contact Lenses Overview 11 3 Products under Development 12 3.1 Contact Lenses - Pipeline Products by Stage of Development 12 3.2 Contact Lenses - Pipeline Products by Segment 13 3.3 Contact Lenses - Pipeline Products by Territory 14 3.4 Contact Lenses - Pipeline Products by Regulatory Path 15 3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 16 3.6 Contact Lenses - Ongoing Clinical Trials 17 4 Contact Lenses - Pipeline Products under Development by Companies 18 4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 18 4.2 Contact Lenses - Pipeline Products by Stage of Development 20 5 Contact Lenses Companies and Product Overview 23 5.1 Aeon Astron Corporation Company Overview 23 5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23 5.2 Alcon, Inc. Company Overview 24 5.2.1 Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24 5.3 Apeliotus Ophthalmics Company Overview 29 5.3.1 Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29 5.4 Auburn University Company Overview 31 5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31 5.5 Axcelon Biopolymers Corp. Company Overview 33 5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33 5.6 Bausch & Lomb Incorporated Company Overview 34 5.6.1 Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34 5.7 Body Organ Biomedical Corp. Company Overview 38 5.7.1 Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38 5.8 Children's Hospital Boston Company Overview 40 5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40 5.9 CooperVision, Inc. Company Overview 42 5.9.1 CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42 5.10 EP Global Communications, Inc. Company Overview 43 5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43 5.11 Euclid Systems Corporation Company Overview 44 5.11.1 Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44 5.12 Eyenovations Company Overview 45 5.12.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45 5.13 EyeYon Medical Company Overview 46 5.13.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46 5.14 Imperial College London Company Overview 49 5.14.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49 5.15 Johnson & Johnson Vision Care, Inc. Company Overview 50 5.15.1 Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50 5.16 Massachusetts Eye and Ear Infirmary Company Overview 54 5.16.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54 5.17 Novartis AG Company Overview 56 5.17.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56 5.18 Ocular Dynamics, LLC Company Overview 57 5.18.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57 5.19 Ocutec Limited Company Overview 58 5.19.1 Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58 5.20 Presbia Plc Company Overview 59 5.20.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59 5.21 Stanford University Company Overview 62 5.21.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62 5.22 The Hong Kong University of Science and Technology Company Overview 63 5.22.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63 5.23 The University of New South Wales Company Overview 64 5.23.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64 5.24 UltraVision CLPL Company Overview 65 5.24.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65 5.25 University of California, San Diego Company Overview 66 5.25.1 University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66 5.26 University of Florida Company Overview 68 5.26.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68 5.27 University of Valencia Company Overview 69 5.27.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69 5.28 University of Washington Company Overview 71 5.28.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71 5.29 University of Western Ontario Company Overview 74 5.29.1 University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74 5.30 Valeant Pharmaceuticals International, Inc. Company Overview 75 5.30.1 Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75 5.31 Visioneering Technologies, Inc. Company Overview 95 5.31.1 Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95 5.32 VISTAKON Pharmaceuticals, LLC Company Overview 101 5.32.1 VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101 5.33 Yolia Health Company Overview 102 5.33.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102 6 Contact Lenses- Recent Developments 103 6.1 Mar 03, 2016: The Cooper Companies Announces First Quarter 2016 Results 103 6.2 Mar 01, 2016: First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits 104 6.3 Feb 19, 2016: Strong growth in revenue and earnings Essilor focused on its 2018 objectives 104 6.4 Feb 12, 2016: Carl Zeiss Meditec Grows, Boosted by Currency Tailwinds / Strongest Growth Once Again in Surgical Ophthalmology 105 6.5 Feb 05, 2016: Briefing Summary of the Analyst/Investor Meeting for the 3rd Quarter Financial Results for the Fiscal Year Ending March 31, 2016 Tokyo, January 29, 2016 106 6.6 Jan 29, 2016: Hoya Reports Third Quarter Results; Record Nine Months Results 109 6.7 Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 110 6.8 Jan 15, 2016: HOYA Presents Hoya EyeGenius 119 6.9 Dec 16, 2015: AEA Investors to Acquire Majority Stake in 1-800 Contacts from Thomas H. Lee Partners 120 6.10 Dec 16, 2015: Carl Zeiss Meditec increases revenue to € 1,040 million / Market shares expanded in a number of markets 120 6.11 Dec 03, 2015: The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results 121 6.12 Nov 10, 2015: Bausch + Lomb Announces 2016 Launch of Bausch + Lomb ULTRA Contact Lenses for Presbyopia 122 6.13 Nov 09, 2015: Unicon Optical to Acquire Taiwan-Based Contact Lenses Company 123 6.14 Nov 06, 2015: Shanghai Conant Optics Plans to Raise up to USD188.6 Million in Private Placement of Shares 123 6.15 Oct 27, 2015: Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance 123 6.16 Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 130 6.17 Oct 12, 2015: EPGL to Grant CooperVision Exclusive Licenses in Exchange for Royalties and Compensation Agreement by November 6, 2015 131 6.18 Oct 08, 2015: Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation 131 6.19 Oct 05, 2015: Presbia Introduces Time-Saving Disposable Microlens Inserter 132 6.20 Sep 17, 2015: Presbia Flexivue Microlens Implanted in More Than 1,000 Patients Worldwide 132 6.21 Sep 17, 2015: QSpex Technologies Enters into Agreement with Shanghai Conant Optical 132 6.22 Sep 14, 2015: HOYA Vision Care Establishes Subsidiary in Turkey 133 6.23 Sep 10, 2015: Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 133 6.24 Sep 10, 2015: Johnson & Johnson Vison Care Launches New Lens With A Tear-Infused Design 133 6.25 Sep 03, 2015: Presbia to Complete Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 134 6.26 Sep 03, 2015: The Cooper Companies Announces Third Quarter 2015 Results 135 6.27 Aug 24, 2015: Results of Patient Outcomes Outside of the U.S. Demonstrate Safety and Effectiveness of Presbia Flexivue Mircolens 136 6.28 Aug 10, 2015: Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment 136 6.29 Aug 05, 2015: Essilor International Raises USD328.4 Million in Public Offering of Notes Due 2017 137 6.30 Aug 03, 2015: Xavier Galliot, Chief Sustainability Officer of the Essilor Group 137 6.31 Jul 30, 2015: Essilor of America to Acquire Vision Source from Brazos Private Equity 137 6.32 Jul 30, 2015: Essilor Announces Strong results ; A winning strategy 137 6.33 Jul 29, 2015: Hoya Announces First Quarter Results Ended June 30, 2015 138 6.34 Jul 29, 2015: Hoya Reports First Quarter Financial Results 140 6.35 Jul 28, 2015: Valeant Pharmaceuticals Presented with Economic Development Support from Rochester Gas & Electric for the Bausch + Lomb ULTRA Contact Lens Manufacturing Line Expansion in Rochester, NY 141 6.36 Jul 21, 2015: Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches 141 6.37 Jul 13, 2015: Valeant Pharma to Acquire Unilens Vision 149 6.38 Jul 09, 2015: Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study 149 6.39 Jun 23, 2015: Bausch + Lomb's Biotrue ONEday for Presbyopia Contact Lenses Now Available in Expanded High Add Powers 149 6.40 Jun 22, 2015: Visioneering Technologies Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue Lenses 150 6.41 Jun 04, 2015: The Cooper Companies Announces Second Quarter 2015 Results 150 6.42 Jun 01, 2015: NVISION Eye Centers Performs First KAMRA Inlay in California 151 6.43 May 15, 2015: Ultravision Expands Licensing Agreement with Art Optical 152 6.44 May 14, 2015: Unilens Vision Reports Third Quarter Operating Results 152 6.45 May 12, 2015: Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit 154 6.46 May 04, 2015: NVISION Eye Centers Becomes One of the First in the U.S. to Offer Breakthrough KAMRA Inlay for Near Vision Loss Associated With Aging 155 6.47 May 03, 2015: Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO 155 6.48 Apr 23, 2015: Novartis delivered sales growth, significant margin expansion and strong innovation in Q1; now with a more focused portfolio 156 6.49 Apr 21, 2015: Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens in Australia 163 6.50 Apr 21, 2015: Revenue up very sharply by 25.4% Annual targets confirmed 163 6.51 Apr 18, 2015: Durrie Vision First in Region to Provide Corneal Implant Designed to Treat Presbyopia 165 6.52 Apr 18, 2015: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges 165 6.53 Apr 17, 2015: FDA approves first-of-its-kind corneal implant to improve near vision in certain patients 167 6.54 Apr 16, 2015: Visioneering Technologies Introduces NaturalVue 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision 168 7 Appendix 169 7.1 Methodology 169 7.2 About GlobalData 171 7.3 Contact Us 172 7.4 Disclaimer 172
List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development 12 Table 2: Contact Lenses - Pipeline Products by Segment 13 Table 3: Contact Lenses - Pipeline Products by Territory 14 Table 4: Contact Lenses - Pipeline Products by Regulatory Path 15 Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16 Table 6: Contact Lenses - Ongoing Clinical Trials 17 Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 18 Table 8: Contact Lenses - Pipeline Products by Stage of Development 20 Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23 Table 10: Body Organ Contact Lens - Product Status 23 Table 11: Body Organ Contact Lens - Product Description 23 Table 12: Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24 Table 13: Dailies Total 1 Colors SiHy Lens - Product Status 24 Table 14: Dailies Total 1 Colors SiHy Lens - Product Description 24 Table 15: Dailies Total 1 Multifocal SiHy Lens - Product Status 25 Table 16: Dailies Total 1 Multifocal SiHy Lens - Product Description 25 Table 17: Dailies Total 1 Toric SiHy Lens - Product Status 26 Table 18: Dailies Total 1 Toric SiHy Lens - Product Description 26 Table 19: Smart Lens - Diabetes - Product Status 27 Table 20: Smart Lens - Diabetes - Product Description 27 Table 21: Weekly WG SiHy Lens - Product Status 28 Table 22: Weekly WG SiHy Lens - Product Description 28 Table 23: Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29 Table 24: Comfort Lens - Product Status 29 Table 25: Comfort Lens - Product Description 29 Table 26: Contact Lens - Glaucoma - Product Status 30 Table 27: Contact Lens - Glaucoma - Product Description 30 Table 28: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31 Table 29: Smart Contact Lenses - Product Status 32 Table 30: Smart Contact Lenses - Product Description 32 Table 31: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33 Table 32: MC - PHEMA Based Contact Lens - Product Status 33 Table 33: MC - PHEMA Based Contact Lens - Product Description 33 Table 34: Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34 Table 35: Ultra Multi Focal Lens - Product Status 35 Table 36: Ultra Multi Focal Lens - Product Description 35 Table 37: Ultra Plus Powers Lens - Product Status 36 Table 38: Ultra Plus Powers Lens - Product Description 36 Table 39: Ultra Toric Lens - Product Status 37 Table 40: Ultra Toric Lens - Product Description 37 Table 41: Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38 Table 42: Biolens - Product Status 39 Table 43: Biolens - Product Description 39 Table 44: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40 Table 45: Contact Lens Drug Delivery Device - Product Status 41 Table 46: Contact Lens Drug Delivery Device - Product Description 41 Table 47: CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42 Table 48: SiH Multifocal - Product Status 42 Table 49: SiH Multifocal - Product Description 42 Table 50: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43 Table 51: EP Global Contact Lens - Product Status 43 Table 52: EP Global Contact Lens - Product Description 43 Table 53: Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44 Table 54: Drug-Eluting Contact Lenses - Product Status 44 Table 55: Drug-Eluting Contact Lenses - Product Description 44 Table 56: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45 Table 57: Drug Dispensing Contact Lens - Product Status 45 Table 58: Drug Dispensing Contact Lens - Product Description 45 Table 59: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46 Table 60: Hyper-CL - Product Status 46 Table 61: Hyper-CL - Product Description 46 Table 62: EyeYon Medical - Ongoing Clinical Trials Overview 47 Table 63: Hyper-CL - Prospective, Randomized Crossover Study of Using the Hyper-CL Lens (Hyper Osmotic Contact Lens) in Subjects Suffering from Corneal Edema 48 Table 64: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49 Table 65: Contact Lens - Product Status 49 Table 66: Contact Lens - Product Description 49 Table 67: Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50 Table 68: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 51 Table 69: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 51 Table 70: Anti-allergic Contact Lens - Product Status 52 Table 71: Anti-allergic Contact Lens - Product Description 52 Table 72: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Status 53 Table 73: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Description 53 Table 74: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54 Table 75: Therapeutic Contact Lens - Product Status 55 Table 76: Therapeutic Contact Lens - Product Description 55 Table 77: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56 Table 78: CLM041 - Product Status 56 Table 79: CLM041 - Product Description 56 Table 80: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57 Table 81: Contact Lens - Dry Eye Disease - Product Status 57 Table 82: Contact Lens - Dry Eye Disease - Product Description 57 Table 83: Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58 Table 84: Third PEG Hydrogel Contact Lens - Product Status 58 Table 85: Third PEG Hydrogel Contact Lens - Product Description 58 Table 86: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59 Table 87: Flexivue Microlens - Product Status 59 Table 88: Flexivue Microlens - Product Description 59 Table 89: Presbia Plc - Ongoing Clinical Trials Overview 60 Table 90: Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia 61 Table 91: Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 61 Table 92: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62 Table 93: Polymer Network Hydrogel Contact Lens - Product Status 62 Table 94: Polymer Network Hydrogel Contact Lens - Product Description 62 Table 95: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63 Table 96: Resonance Circuit Sensor Contact Lens - Product Status 63 Table 97: Resonance Circuit Sensor Contact Lens - Product Description 63 Table 98: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64 Table 99: Stem Cell Contact Lens - Product Status 64 Table 100: Stem Cell Contact Lens - Product Description 64 Table 101: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65 Table 102: Contact Lenses - Product Status 65 Table 103: Contact Lenses - Product Description 65 Table 104: University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66 Table 105: Aerated Contact Lens - Product Status 66 Table 106: Aerated Contact Lens - Product Description 66 Table 107: Telescopic Contact Lens - Product Status 67 Table 108: Telescopic Contact Lens - Product Description 67 Table 109: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68 Table 110: Vitamin E - Packed Lenses - Product Status 68 Table 111: Vitamin E - Packed Lenses - Product Description 68 Table 112: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69 Table 113: Multifocal Contact Lens - Myopia - Product Status 69 Table 114: Multifocal Contact Lens - Myopia - Product Description 69 Table 115: Multifocal Contact Lens - Presbyopia - Product Status 70 Table 116: Multifocal Contact Lens - Presbyopia - Product Description 70 Table 117: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71 Table 118: Bionic Contact Lens - Product Status 72 Table 119: Bionic Contact Lens - Product Description 72 Table 120: Solar Powered Augmented Lenses - Product Status 73 Table 121: Solar Powered Augmented Lenses - Product Description 73 Table 122: University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74 Table 123: Nanocomposite Hydrogel Lenses - Product Status 74 Table 124: Nanocomposite Hydrogel Lenses - Product Description 74 Table 125: Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75 Table 126: BLC - 001: SVS - Product Status 76 Table 127: BLC - 001: SVS - Product Description 76 Table 128: BLC - 002: SVS - Product Status 77 Table 129: BLC - 002: SVS - Product Description 77 Table 130: BLC - 003: SVS/MF/fA - Product Status 78 Table 131: BLC - 003: SVS/MF/fA - Product Description 78 Table 132: BLC - 004: Toric - Product Status 79 Table 133: BLC - 004: Toric - Product Description 79 Table 134: BLC - 005: SVS/MF - Product Status 80 Table 135: BLC - 005: SVS/MF - Product Description 80 Table 136: BLC - 006: SVS - Product Status 81 Table 137: BLC - 006: SVS - Product Description 81 Table 138: BLC - 007: MF - Product Status 82 Table 139: BLC - 007: MF - Product Description 82 Table 140: BLC - 008: Astigmatism - Product Status 83 Table 141: BLC - 008: Astigmatism - Product Description 83 Table 142: BLC - 009: Astigmatism - Product Status 84 Table 143: BLC - 009: Astigmatism - Product Description 84 Table 144: XUV - 003: Aphakia - Product Status 85 Table 145: XUV - 003: Aphakia - Product Description 85 Table 146: XUV - 004: SVS - Product Status 86 Table 147: XUV - 004: SVS - Product Description 86 Table 148: XUV - 007: MF - Product Status 87 Table 149: XUV - 007: MF - Product Description 87 Table 150: XUV - 009: SVS - Product Status 88 Table 151: XUV - 009: SVS - Product Description 88 Table 152: XUV - 010: Astigmatism - Product Status 89 Table 153: XUV - 010: Astigmatism - Product Description 89 Table 154: XUV - 011: MF - Product Status 90 Table 155: XUV - 011: MF - Product Description 90 Table 156: XUV - 012: SVS - Product Status 91 Table 157: XUV - 012: SVS - Product Description 91 Table 158: XUV - 013: SVS - Product Status 92 Table 159: XUV - 013: SVS - Product Description 92 Table 160: XUV - 014: Presbyopia - Product Status 93 Table 161: XUV - 014: Presbyopia - Product Description 93 Table 162: XUV - 015: MF - Product Status 94 Table 163: XUV - 015: MF - Product Description 94 Table 164: Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95 Table 165: Contact Lens - Product Status 96 Table 166: Contact Lens - Product Description 96 Table 167: NaturalVue Sphere 1 Day Contact Lenses - Product Status 97 Table 168: NaturalVue Sphere 1 Day Contact Lenses - Product Description 97 Table 169: NaturalVue Toric 1 Day Contact Lenses - Product Status 98 Table 170: NaturalVue Toric 1 Day Contact Lenses - Product Description 98 Table 171: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 99 Table 172: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 99 Table 173: VTI MPC Lens - Product Status 100 Table 174: VTI MPC Lens - Product Description 100 Table 175: VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101 Table 176: K-Lens - Product Status 101 Table 177: K-Lens - Product Description 101 Table 178: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102 Table 179: TVT Device - Product Status 102 Table 180: TVT Device - Product Description 102 Table 181: Glossary 170


List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development 12 Figure 2: Contact Lenses - Pipeline Products by Segment 13 Figure 3: Contact Lenses - Pipeline Products by Territory 14 Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 15 Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16 Figure 6: Contact Lenses - Ongoing Clinical Trials 17

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...
Choose License Type
Single User - US $4000
Multi User - US $8000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify